- Poster presentations to highlight data and potential
advantages of drug candidates from first-in-class series of
compounds targeting HDAC, EGFR and Her2, and HDAC, Abl and Src
family kinases -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 15, 2010 - Curis, Inc.
(NASDAQ: CRIS), a drug development company seeking to develop next
generation targeted small molecule drug candidates for cancer
treatment, today announced that Curis scientists and collaborators
will present data from two of its proprietary drug candidates at
the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and
Cancer Therapeutics” held in Berlin, Germany, November 16-19,
2010.

Rudi Bao, M.D., Ph.D., Curis' Senior
Director of Oncology, will present a poster entitled,
“Anti-Tumor Activity of CU-201, an Inhibitor of HDAC, SFK and
Abl Kinases,” as part of the poster session on
“Molecular-targeted therapies-preclinical” on November
17, 2010, at 12:00 pm CET.

Toshio Shimizu, M.D., Ph. D., Visiting
Clinical Fellow, South Texas Accelerated Research Therapeutics
(START), will present a poster entitled, “The First-in-Human,
First-in-Class Study of CUDC-101, a Multi-Targeted Inhibitor of
HDAC, EGFR and HER2: A Phase I Study in Patients with Advanced
Cancer,” as part of the poster session on "Molecular-targeted
therapies-clinical trials," which is scheduled on November 18,
2010, at 12:00 pm CET.

Copies of the posters will be available on Curis' website,
www.curis.com, following the presentations.

About Curis, Inc.

Curis is a drug development company that is committed to
leveraging its innovative signaling pathway drug technologies to
seek to create new targeted small molecule drug candidates for
cancer. Curis is building upon its previous experiences in
targeting signaling pathways, including in the Hedgehog pathway, in
its effort to develop proprietary targeted cancer programs. For
more information, visit Curis' website at
www.curis.com.

Curis Cautionary Statement: This press release may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements used in this press release may contain the words
"believes", "expects", "anticipates", "plans", "seeks",
"estimates”, “assumes”, "will", "may" or similar
expressions. These forward-looking statements are not guarantees of
future performance and involve risks, uncertainties, assumptions
and other important factors that may cause the actual results to be
materially different from those indicated by such forward-looking
statements including, among other things Those risk factors
identified in Curis' Quarterly Report on Form 10-Q for the quarter
ended September 30, 2010 and other filings that it periodically
makes with the Securities and Exchange Commission.

In addition, any forward-looking statements represent the
views only as of today and should not be relied upon as
representing Curis' views as of any subsequent date. Curis
disclaims any intention or obligation to update any of the
forward-looking statements after the date of this press release
whether as a result of new information, future events or
otherwise.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.